Clinical trials on Malignant Melanoma

Malignant melanoma is a severe form of skin cancer that originates in the melanocytes, the cells that produce melanin, which gives skin its color. This type of cancer can develop from existing moles or appear as new dark spots on the skin. Malignant melanoma is known for its potential to spread rapidly to other parts of the body if not detected and treated early. Complications
  • Metastasis: Melanoma can spread to other organs, such as the lungs, liver, brain, and bones, leading to severe organ dysfunction and failure.
  • Chronic Pain: Tumor growth and metastasis can cause persistent and severe pain, significantly impacting quality of life.
  • Lymphatic Obstruction: Spread to lymph nodes can result in lymphedema, causing swelling and discomfort.
  • Neurological Issues: Metastasis to the brain can lead to cognitive impairments, seizures, and other serious neurological deficits.
  • Respiratory Problems: Metastasis to the lungs can cause breathing difficulties and reduced lung function.
  • Liver Dysfunction: Metastasis to the liver can result in jaundice and other liver-related issues.
  • Bone Fractures: Metastasis to the bones increases the risk of fractures and severe pain, affecting mobility and overall health.
Treatment Methods
  • Immunotherapy: Uses drugs such as pembrolizumab, nivolumab, and ipilimumab to enhance the immune system’s ability to fight cancer cells.
  • Targeted Therapy: Involves medications like vemurafenib, dabrafenib, and trametinib that target specific genetic mutations in melanoma cells.
  • Chemotherapy: Utilizes drugs such as dacarbazine and temozolomide to kill rapidly dividing cancer cells.
  • Radiation Therapy: Employs high-energy radiation to destroy cancer cells and shrink tumors, often used for brain metastases.
  • Combination Therapy: Combines different treatments, such as targeted therapy and immunotherapy, to improve effectiveness.
Prognosis The prognosis for malignant melanoma depends on the stage of the disease at diagnosis and the effectiveness of the treatments used. Early detection and treatment significantly improve survival rates and quality of life. Advanced stages of melanoma with metastasis have a more challenging prognosis, but advances in treatment options have improved outcomes for many patients. Without treatment, malignant melanoma can progress rapidly, leading to significant health deterioration and reduced life expectancy. Early detection and aggressive treatment are crucial for improving outcomes and extending survival.
  • CT-EU-00117557

    Study of a new anticancer vaccine (SCIB1) in combination with immunotherapeutic drugs in the treatment of malignant melanoma

    The aim of this clinical trial is to test whether a new cancer vaccine called SCIB1 can be safely used with two approved treatments for advanced melanoma – nivolumab (Opdivo) plus ipilimumab (Yervoy) or pembrolizumab (Keytruda). The study will also examine whether adding SCIB1 to these therapies can increase the chances of melanoma responding to treatment and the duration of that response.

    Currently, SCIB1 is still considered experimental, but has been previously administered to melanoma patients and was well tolerated. Scientists have even seen some signs that it may help stimulate the immune system to fight cancer. In this study, SCIB1 will be administered up to 10 times over 85 weeks by injection into the arm or leg using a special needle-free device. Before starting treatment, you will undergo several screening tests to make sure you are eligible to take part.

    • SCIB1 DNA vaccine
  • Pembrolizumab and electrochemotherapy performed using a cliniporator in the treatment of malignant melanoma

    This study is looking at the use of pembrolizumab (Keytruda) in combination with a treatment called electrochemotherapy (ECT) in people with malignant melanoma. The main goal is to see if combining these two treatments is safe and can improve the effectiveness of the therapy in shrinking tumors, both those on the surface of the skin and those found in the body.

    Electrochemotherapy involves using electrical pulses along with a drug called Bleomycin to kill cancer cells. This is thought to help the immune system better recognize and attack cancer. Pembrolizumab is an immunotherapy drug that inhibits the cells of the immune system that fight cancer. Scientists believe that by combining these two approaches, a better anti-tumor response can be achieved compared to using pembrolizumab alone.

    • Pembrolizumab KEYTRUDA®